YOKNE'AM ILLIT, Israel—Lumenis Ltd., a leading energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multi-center, double-blinded, randomized controlled FDA trial showed that Lumenis IPL with patented Optimal Pulse Technology (OPT) significantly improved tear breakup time, meibum quality, and meibomian gland expressibility, according to Lumenis. The clinical trial joins a long list of studies of Lumenis' IPL with OPT that have shown the same results, as well as reduction of inflammatory markers.

Subsequent to the FDA approval, Lumenis is launching OptiLight, a bright solution for dry eyes. OptiLight with Lumenis’ patented OPT technology is designed for a consistent, precise, and controlled light-based treatment of signs of dry eye disease.

“We deal with dry eye every day, but unless we address the underlying inflammation, it’s difficult to meaningfully impact the disease. OptiLight helps us to address the inflammation, as shown in Lumenis' IPL clinical trials, and improves signs of dry eye disease due to MGD, positioning it as a valuable tool in our dry eye toolkit,” said Dr. Steven J. Dell, medical director of Dell Laser Consultants and lead investigator in the Lumenis’ clinical trial submitted to the FDA.

Lumenis will unveil the new OptiLight at a formal virtual launch event on May 13, 2021, 7 p.m. EDT. Register at: www.lumenis.com\optilight.